Champions Oncology Inc Total Assets
Champions Oncology Inc total assets. Based on the latest financial reports, Champions Oncology Inc (CSBR) holds total assets worth $28.45 Million USD as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CSBR company net worth for the company's overall valuation and market capitalisation.
Total Assets of Champions Oncology Inc (1996–2025)
Total assets of Champions Oncology Inc from 1996 to 2025. This chart illustrates how Champions Oncology Inc's total assets have evolved over time, based on quarterly financial data. See CSBR live share price for real-time trading data and today's change.
Champions Oncology Inc - Asset Composition Analysis
Champions Oncology Inc Total Assets Breakdown (April 2025)
Champions Oncology Inc total assets breakdown as of April 2025. Champions Oncology Inc's total assets of $28.45 Million consist of 69.2% current assets and 30.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.3% |
| Accounts Receivable | $11.23 Million | 34.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $335.00K | 1.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Champions Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CSBR working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Champions Oncology Inc's current assets represent 69.2% of total assets in 2025, an increase from 33.8% in 1996.
- Cash Position: Cash and equivalents constituted 30.3% of total assets in 2025, up from 18.9% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 34.7% of total assets.
Champions Oncology Inc Competitors by Total Assets
Key competitors of Champions Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Champions Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.98 | 0.99 | 1.13 |
| Quick Ratio | 0.98 | 0.99 | 1.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-492.00K | $-173.00K | $1.43 Million |
Champions Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Champions Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.97 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | 23.8% |
| Total Assets | $32.34 Million |
| Market Capitalization | $67.07 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Champions Oncology Inc's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Champions Oncology Inc's assets grew by 23.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Champions Oncology Inc (1996–2025)
The table below shows the annual total assets of Champions Oncology Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $32.34 Million | +23.77% |
| 2024-04-30 | $26.13 Million | -23.84% |
| 2023-04-30 | $34.31 Million | -3.02% |
| 2022-04-30 | $35.38 Million | +28.22% |
| 2021-04-30 | $27.59 Million | +32.96% |
| 2020-04-30 | $20.75 Million | +84.21% |
| 2019-04-30 | $11.27 Million | +39.45% |
| 2018-04-30 | $8.08 Million | +0.84% |
| 2017-04-30 | $8.01 Million | +38.67% |
| 2016-04-30 | $5.78 Million | -52.05% |
| 2015-04-30 | $12.05 Million | +35.86% |
| 2014-04-30 | $8.87 Million | -24.17% |
| 2013-04-30 | $11.69 Million | +68.93% |
| 2012-04-30 | $6.92 Million | -45.28% |
| 2011-04-30 | $12.65 Million | +221.72% |
| 2010-04-30 | $3.93 Million | -14.89% |
| 2009-04-30 | $4.62 Million | -0.67% |
| 2008-04-30 | $4.65 Million | +2431.25% |
| 2007-04-30 | $183.76K | +33929.26% |
| 2006-04-30 | $540.00 | -99.80% |
| 2005-04-30 | $266.54K | -31.99% |
| 2004-04-30 | $391.92K | -19.55% |
| 2003-04-30 | $487.17K | -38.00% |
| 2002-04-30 | $785.69K | -10.33% |
| 2001-04-30 | $876.24K | -38.14% |
| 2000-04-30 | $1.42 Million | +4.92% |
| 1999-04-30 | $1.35 Million | +1.50% |
| 1998-04-30 | $1.33 Million | +33.00% |
| 1997-04-30 | $1.00 Million | +35.14% |
| 1996-04-30 | $740.00K | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more